S3V Vascular Technologies Unlisted Shares
S3V Vascular Technologies – Launches Indigenous Transcatheter Aortic Valve Replacement System
Money Control
2 min read
Expert Analysis:
S3V Vascular Technologies, backed by former L&T chairman A.M. Naik along with investors Utpal Sheth and Madhu Kela, has unveiled India’s first indigenous balloon-expandable Transcatheter Aortic Valve Replacement (TAVR) system.
TAVR is a minimally invasive alternative to open-heart surgery used to treat severe aortic stenosis and is widely adopted globally for elderly or high-risk patients.
The domestically engineered device aims to reduce dependence on imported heart-valve implants, which currently cost ₹13 lakh to ₹23 lakh per device, significantly limiting access to the procedure in India.
India currently performs around 4,000 TAVR procedures annually, despite an estimated clinical demand of nearly 50,000 cases, highlighting the large treatment gap the innovation seeks to address.
The system has entered preclinical testing, and subject to regulatory approvals, the company expects a commercial rollout within 12–18 months.
Key Takeaway:
S3V’s indigenous TAVR system could significantly lower device costs and expand access to advanced cardiac treatment in India, addressing a large unmet demand where only ~4,000 procedures are performed annually against a need of ~50,000.
Precize Daily Pulse
The latest news in the world of Unlisted Shares, summarised by our experts.
Company
Our Office
Office No. 1219, The Summit Business Park, Andheri Kurla Road, Andheri East, Mumbai, Maharashtra - 400093
Find us on Googlesupport@precize.in
+91 7738336457
All trademarks and logos or registered trademarks and logos found on this Site or mentioned herein belong to their respective owners and are solely used for informational and educational purposes.
The material presented in this advertisement is for informational purposes only and should not be construed as investment advice or investment availability. It is not a recommendation of, or an offer to sell or solicitation of an offer to buy, any particular unlisted share, security, strategy, or investment product. Investing in the private market and securities involves risks, including the potential loss of money, and past performance does not guarantee future results. Market trends, data interpretations, graph projections are provided for informational and illustrative purposes and may not reflect actual future performance. Nothing on this website should be construed as personalized investment advice or should not be treated as legal, financial, or any other form of advice. Precize is not liable for financial or any other form of loss incurred by the user or any affiliated party based on information provided herein.
Precize is neither a stock exchange nor does it intend to get recognized as a stock exchange under the Securities Contracts Regulation Act, 1956. Precize is not authorized by the capital markets regulator to solicit investments. The securities traded on these platforms are not traded on any regulated exchange.
The website will be updated regularly.
Copyright © 2026 - Precize - All Rights Reserved